Natera CEO Steven Chapman sells $545,000 in stock amid strong growth reports

Natera CEO Steven Chapman sold 1,698 shares of common stock on September 1, 2026, for approximately $545,000. The transaction was executed under a Rule 10b5-1 plan, which allows insiders to schedule sales in advance. Following the sale, Chapman maintains a direct ownership stake of approximately 98,199 shares, representing about 0.06% of the company's total equity.

Separately, Natera executives Steve Chapman and CFO Mike Brophy presented at the Morgan Stanley 24th Annual Global Healthcare Conference. During the presentation, Chapman highlighted strong second-quarter performance, noting nearly 40% year-over-year sales growth and record sequential Signatera test volumes. He emphasized the significant market opportunity within the minimal residual disease (MRD) sector.